The impact of tumor cavitations on objective and metabolic response assessment in a phase II study of erlotinib and sorafenib in patients with advanced non-small cell lung cancer (NSCLC)

J.S.W. Lind, E.F. Smit, H.J.M. Groen, A.C. Dingemans, O.S. Hoekstra, V. Frings

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)S596-S597
JournalJournal of Thoracic Oncology
Issue number9
Publication statusPublished - 2009

Cite this